Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$232,395
-$248,265 QoQ
Shares Held
11,585
-25.8% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026TWO SIGMA INVESTMENTS, LP holds $5,506,832,621 across 316 Biotechnology names. LYEL ranks #262 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,992,577 | $659,283,951 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
812,236 | $627,566,023 | |
| 3 | MRNA |
Moderna, Inc.
|
9,086,404 | $461,589,323 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
5,857,629 | $439,849,361 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
3,120,631 | $231,738,058 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
378,146 | $168,857,314 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
1,558,807 | $151,593,980 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
4,432,142 | $144,221,900 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $232,395 | 11,585 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $480,660 | 15,616 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $338,230 | 20,827 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $88,921 | 10,059 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||